The importance of analyzing graft and patient survival by cause of failure: An example using pediatric small intestine transplant data

Transplantation

Volumn 81, Issue 8, 2006, Pages 1133-1140

  Gaynor, Jeffrey J ^a   Kato, Tomoaki ^a   Selvaggi, Gennaro ^a   Moon, Jang I ^a   Levi, David M ^a   Nishida, Seigo ^a   Madariaga, Juan R ^a   Weppler, Debbie ^a   Ruiz, Phillip ^a   Tzakis, Andreas G ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Cause specific failure; Hazard rate; Pediatric small intestine transplantation; Prognostic factors

Indexed keywords

CYCLOPHOSPHAMIDE; DACLIZUMAB; OKT 3;

ARTICLE; CLINICAL ARTICLE; DEATH; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; INFECTION; INTESTINE GRAFT; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS;

COHORT STUDIES; GRAFT SURVIVAL; HUMANS; INFANT; INTESTINE, SMALL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TREATMENT FAILURE;

EID: 33646773569     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000205754.58604.a8     Document Type: Article

References (37)

1. Jain A, Reyes J, Kashyap R, et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000; 232(4): 490-500.
2. Jain A, Mazariegos G, Kashyap R, et al. Pediatric liver transplantation: A single center experience spanning 20 years. Transplantation 2002; 73(6): 941-947.
3. Martin SR, Atkison P, Anand R, Lindblad AS, and the SPLIT Research Group. Studies of pediatric liver transplantation 2002: Patient and graft survival and rejection in pediatric recipients of a first liver transplant in the United States and Canada. Ped Transplant 2004; 8: 273-283.
4. Vogt DP, Henderson JM, Carey WD, Barnes D. The long-term survival and causes of death in patients who survive at least 1 year after liver transplantation. Surgery 2002; 132: 775-780.
5. Todo S, Reyes J, Furukawa H, et al. Outcome analysis of 71 clinical intestinal transplantations. Ann Surg 1995; 222(3): 270-282.
6. Grant D. Current results of intestinal transplantation. Lancet 1996; 347: 1801-1803.
7. Abu-Elmagd K, Reyes J, Bond G, et al. Clinical intestinal transplantation: A decade of experience at a single center. Ann Surg 2001; 234(3): 404-117.
8. Farmer DG, McDiarmid SV, Yersiz H, et al. Outcome after intestinal transplantation: Results from one center's 9-year experience. Arch Surg 2001; 136: 1027-1032.
9. Kato T, Ruiz P, Thompson JF, et al. Intestinal and multivisceral transplantation. World J Surg 2002; 26: 226-237.
10. Nishida S, Levi D, Kato T, et al. Ninety-five cases of intestinal transplantation at the University of Miami. J Gastrointestinal Surg 2002; 6: 233-239.
11. Fishbein TM, Kaufman SS, Florman SS, et al. Isolated intestinal transplantation: Proof of clinical efficacy. Transplantation 2003; 76(4): 636-640.
12. Kato T, Mittal N, Nishida S, et al. The role of intestinal transplantation in the management of babies with extensive gut resections. J Ped Surg 2003; 38(2): 145-149.
13. Kato T, Gaynor JJ, Selvaggi G, et al. Intestinal transplantation in children: A summary of clinical outcomes and prognostic factors in 108 patients from a single center. J Gastrointestinal Surg 2005; 9: 75-89.
14. Grant D, Abu-Elmagd K, Reyes J, et al on behalf of the Intestine Transplant Registry. 2003 report of the Intestine Transplant Registry: A new era has dawned. Ann Surg 2005; 241(4): 607-613.
15. Intestinal Transplant Registry Data. Current Results. Available at: http://www.intestinaltransplant.org/.
16. Hanto DW, Fishbein TM, Pinson CW, et al. Liver and intestine transplantation: Summary analysis, 1994-2003. Am J Transplant 2005; 5(2): 916-933.
17. Tzakis AG, Kato T, Levi DM, et al. One hundred multivisceral transplants at a single center. Ann Surg 2005; 242: 480-493.
18. Tzakis AG, Kato T, Nishida S, et al. Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. Transplantation 2003; 75(9): 1512-1517.
19. Levi DM, Tzakis AG, Kato T, et al. Transplantation of the abdominal wall. Lancet 2003; 361(9376): 2173-2176.
20. Kato T, O'Brien CB, Nishida S, et al. The first case report of the use of a zoom videoendoscope for the evaluation of small bowel graft mucosa in a human after intestinal transplantation. Gastrointestinal Endoscopy 1999; 50(2): 257-262.
21. Lee RG, Nakamura K, Tsamandas AC, et al. Pathology of human intestinal transplantation. Gastroenterology 1996; 110: 1820-1834.
22. Ruiz P, Bagni A, Brown R, et al. Histological criteria for the identification of acute cellular rejection in human small bowel allografts: Results of the pathology workshop at the VIII International Small Bowel Transplant Symposium. Transplant Proc 2004; 36: 335-337.
23. Cox DR. Regression models and life tables (with discussion). J Royal Stat Soc B 1972; 34: 187-220.
24. Prentice RL, Kalbfleisch JD, Peterson A, et al. The analysis of failure times in the presence of competing risks. Biometrics 1978; 34: 541-554.
25. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley and Sons, Inc., 1980.
26. Gaynor J, Chapman D, Little C, et al. A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia (ALL): The Memorial Hospital experience since 1969. J Clin Oncol 1988; 6: 1317-1329.
27. Gaynor JJ, Tan CC, Casper ES, et al. Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: A study of 423 adults. J Clin Oncol 1992; 10: 1317-1329.
28. Yamashiki N, Gaynor JJ, Kato T, et al. Competing risks analysis of predictors of delisting owing to tumor progression in liver transplant candidates with hepatocellular carcinoma. Am J Transplant 2004; 4: 774-781.
29. Lawless JF. Statistical Models and Methods for Lifetime Data. New York: John Wiley and Sons, 1982.
30. Gaynor JJ, Feuer EJ, Tan CC, et al. On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data. J Am Stat Assoc 1993; 88: 400-409.
31. Lesser ML, CentoSJ. Tables of power for the F-test for comparing two exponential survival distributions. J Chronic Dis 1981; 34: 533-544.
32. Pintilie M. Dealing with competing risks: Testing covariates and calculating sample size. Stat Med 2002; 21: 3317-3324.
33. Murase N, Demetris AJ, Matsuzaki T, et al. Long survival in rats after multivisceral versus isolated small-bowel allotransplanttion under FK 506. Surgery 1991; 110: 87-98.
34. Calne R, Davies, H. Organ graft tolerance: The liver effect. Lancet 1994; 343: 67-68.
35. Edwards-Smith C, Goto S, Lord R, et al. Allograft acceptance and rejection, mediated by a liver suppressor factor, LSF-1, purified from serum of liver transplanted rats. Transpl Immunol 1996; 4: 287-292.
36. Wiesner RJ, McDiarmid SV, Kamath PS, et al. MELD and PELD: Application of survival models to liver allocation. Liver Transplant 2001; 7(7): 567-580.
37. McDiarmid SV, Anand R, Lindblad AS, and the Principal Investigators and Institutions of the Studies of Pediatric Liver Transplantation (SPLIT) Research Group. Development of a pediatric end-stage liver disease score to predict poor outcome in children awaiting liver transplantation. Transplantation 2002; 74(2):173-181.